Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 144 of the 145 references it cites were found in a registry or an index.

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis

Open access

Abstract

Objective: To estimate the association between the use of sodium glucose co-transporter-2 (SGLT2) inhibitors and postmarket harms as identified by drug regulatory agencies. Design: We conducted a systematic review and meta-analysis of randomised controlled trials (RCT). Six large databases were searched from inception to May 2018. Random effects models were used to estimate pooled relative risks (RRs). Intervention: SGLT2 inhibitors, compared with placebo or active comparators. Primary outcomes: Acute kidney injury (AKI), diabetic ketoacidosis (DKA), urinary tract infections (UTI), bone fractures and lower limb amputations. Results: We screened 2418 citations of which 109 were included. Most studies included one of four SGLT2 inhibitors, dapagliflozin, canagliflozin, empagliflozin and ipragliflozin. When compared with placebo, SGLT2 inhibitors were found to be significantly protective against AKI (RR=0.59; 95% CI 0.39 to 0.89; I 2=0.0%), while no difference was found for DKA (RR 0.66; 95% CI 0.30 to 1.45, I 2=0.0%), UTI (RR 1.02; 95% CI 0.95 to 1.09, I 2=0.0%) or bone fracture (RR 0.87; 95% CI 0.69 to 1.09, I 2=1.3%). Three studies reported on amputation, with one finding a significant increase risk. No increased risk for either outcome was found when compared with active controls. Subgroup analysis did show an increased risk of UTI with dapagliflozin only (RR 1.21; 95% CI 1.02 to 1.43, I 2=0.0%), but no other analysis supported an increased risk of AKI, DKA, UTI or fracture. Conclusions: Current evidence from RCTs does not suggest an increased risk of harm with SGLT2 inhibitors as a class over placebo or active comparators with respect to AKI, DKA, UTI or fracture. However, wide CIs for many comparisons suggest limited precision, and therefore clinically important adverse events cannot be ruled out. Dapagliflozin, appears to independently increase the risk of UTI, although the mechanism for this intraclass variation in risk is unclear. PROSPERO registration number: CRD42016038715.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2018-022577

Cites

144 of 144 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow diagram for included studies.
Figure 1 Flow diagram for included studies.CC BY-NC · PubMed Central
Figure 2 Risk of acute kidney injury (AKI) with sodium glucose co-transporter-2 (SGLT2) inhibitors compared with placebo.
Figure 2 Risk of acute kidney injury (AKI) with sodium glucose co-transporter-2 (SGLT2) inhibitors compared with placebo.CC BY-NC · PubMed Central
Figure 3 Risk of diabetic ketoacidosis (DKA) from sodium glucose co-transporter-2 (SGLT2) inhibitors compared with placebo.
Figure 3 Risk of diabetic ketoacidosis (DKA) from sodium glucose co-transporter-2 (SGLT2) inhibitors compared with placebo.CC BY-NC · PubMed Central
Figure 4 Risk of urinary tract infection (UTI) with sodium glucose co-transporter-2 (SGLT2) inhibitor compared with placebo.
Figure 4 Risk of urinary tract infection (UTI) with sodium glucose co-transporter-2 (SGLT2) inhibitor compared with placebo.CC BY-NC · PubMed Central
Figure 5 Risk of urinary tract infection (UTI) with sodium glucose co-transporter-2 (SGLT2) inhibitors compared with other active treatments.
Figure 5 Risk of urinary tract infection (UTI) with sodium glucose co-transporter-2 (SGLT2) inhibitors compared with other active treatments.CC BY-NC · PubMed Central
Figure 6 Risk of fracture with sodium glucose co-transporter-2 inhibitors compared with placebo.
Figure 6 Risk of fracture with sodium glucose co-transporter-2 inhibitors compared with placebo.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 145 references

Research works printed but not linked: 4

  1. Health Canada. Summary Safety Review - Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors INVOKANA (canagliflozin) and FORXIGA (dapagliflozin) - Evaluation of a Potential Risk of Acute Kidney Injury. 2015 http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/sglt2-eng.php (Accessed 10 Dec 2015).
  2. Health Canada Forxiga, Invokana. Health Canada begins safety review of diabetes drugs known as SGLT2 inhibitors and risk of ketoacidosis. http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/53892a-eng.php (Accessed 10 Dec 2015).
  3. Maldonado-Lutomirsky, 2016, Empagliflozin (EMPA) as add-on to linagliptin (LINA) and metformin in patients with type 2 diabetes (T2DM): A 24-week randomised, double-blind, parallel-group trial, Diabetologia, 59, S93
  4. 10.1056/NEJMoa1504720 · DOI · Paper page

Cited by

See all 222

Metadata

Authors
Donnan, J. R., Grandy, C. A., Chibrikov, E., Marra, C. A., Aubrey-Bassler, K., Johnston, K., Swab, M., Hache, J., Curnew, D., Nguyen, H., & Gamble, J.-M.
Affiliations
Memorial University of Newfoundland (CA)
Corresponding author
Gamble, John-Michael
Venue
BMJ Open
Publisher
BMJ
Published
2019-01
Volume
9
Issue
1
Pages
e022577
ISSN
2044-6055 (ISSN-L)
OpenAlex
W2913306188
Cited by
222
References
145
Citations by year
2026: 17 · 2025: 15 · 2024: 35 · 2023: 33 · 2022: 34 · 2021: 37 · 2020: 36 · 2019: 14
FWCI
4.64
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ Open (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Canadian Diabetes Association
  • Newfoundland and Labrador Centre for Applied Health Research
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
SGLT2 inhibitors, dapagliflozin, canagliflozin, empagliflozin, ipragliflozin, acute kidney injury, diabetic ketoacidosis, urinary tract infection, bone fractures, lower limb amputation, drug safety, adverse drug reactions, type 2 diabetes
MeSH terms
Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Amputation, Surgical, Benzhydryl Compounds, Glucosides, Humans, Thiophenes, Urinary Tract Infections, Randomized Controlled Trials as Topic, Diabetic Ketoacidosis, Fractures, Bone, Acute Kidney Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1136/bmjopen-2018-022577
The paper
Donnan, J. R., Grandy, C. A., Chibrikov, E., Marra, C. A., Aubrey-Bassler, K., Johnston, K., Swab, M., Hache, J., Curnew, D., Nguyen, H., & Gamble, J.-M. (2019). Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open. https://doi.org/10.1136/bmjopen-2018-022577

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.